Related Experiment Video

Updated: May 5, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer

Maulik Vyas1, Ulrike Koehl2, Michael Hallek1

  • 1University of Cologne, Clinic 1 for Internal Medicine, 50924 Cologne, Germany.

Trends in Molecular Medicine
|November 26, 2013
PubMed

Insights

Targeted immunotherapies harness the immune system to fight cancer by activating T cells and natural killer (NK) cells. Overcoming tumor-induced immune suppression is key for effective cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • The immune system possesses the inherent capability to eliminate tumor cells, a principle underpinning targeted immunotherapies.
  • Current immunotherapies aim to activate key immune receptors like CD3 on T cells and NKG2D/NKp30 on natural killer (NK) cells.
  • A significant hurdle in cancer immunotherapy is overcoming immune suppression within the tumor microenvironment.

Purpose of the Study:

  • To explore novel recombinant constructs designed to enhance antitumor immune responses.
  • To circumvent immunosuppressive mechanisms employed by malignant cells and the tumor microenvironment.
  • To develop strategies for more effective cancer immunotherapy.

Main Methods:

  • Development of recombinant constructs in various formats.
  • Utilizing natural ligands (immunoligands) or antibody-derived components (immunoconstructs).
  • Focusing on activating immune cells like T cells and NK cells.

Main Results:

  • Engineered constructs show potential in activating immune cells against tumors.
  • Strategies developed to bypass tumor-induced immune suppression.
  • Demonstrated feasibility of using immunoligands and immunoconstructs.

Conclusions:

  • Recombinant constructs offer a promising avenue for overcoming immune suppression in cancer.
  • Targeted activation of immune receptors on T cells and NK cells is crucial for therapeutic efficacy.
  • Further development of immunoligands and immunoconstructs could significantly advance cancer immunotherapy.
Keywords:
NK cellsT cellscancerimmunoconstructsimmunoligandsrecombinant proteins

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

8.9K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.9K
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.4K